Table 1. Summary of in vitro antiviral properties of iminosugars.
| Stereochemistry | Class | Drug | EC50a (μM) | MNTDb (μM) | Enhancementc (fold) |
|---|---|---|---|---|---|
| Glucose | DNJ | DNJ | 308 (273–347) | 10000 | n.d.d |
| NB-DNJ | 10.6 (7.77–14.5) | 100 | 29 | ||
| NN-DNJ | 1.25 (1.05–1.48) | 31.6 | 246 | ||
| Castanospermine | Castanospermine | 36.4 (26.0–51.0) | 100 | n.d. | |
| Celgosivir | 5.17 (3.69–7.24) | 100 | 7 | ||
| Galactose | DGJ | NB-DGJ | n.d. | 100 | n.d. |
| NN-DGJ | n.d. | 31.6 | n.d. |
aEC50 is given as the estimated value with 95% confidence interval in parentheses.
bMNTD is the maximum non-toxic dose tested.
cEnhancement is the fold improvement of antiviral EC50 for the compound of interest in comparison to the parent compound (e.g. EC50 DNJ/EC50 NB-DNJ = 29).
dn.d. indicates that a value could not be determined.